Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010
February 08 2010 - 8:00AM
PR Newswire (US)
ALISO VIEJO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Valeant
Pharmaceuticals International (NYSE:VRX) today announced that it
will host a conference call and a live Internet webcast along with
a slide presentation on Monday, February 22, 2010 at 10:00 a.m. EST
(7:00 a.m. PST) to discuss results for the 2009 fourth quarter and
year. The dial-in number to participate on this call is (877)
295-5743, confirmation code 53708100. International callers should
dial (973) 200-3961, confirmation code 53708100. A replay will be
available approximately two hours following the conclusion of the
conference call to Monday, March 1, 2010, and can be accessed by
dialing (800) 642-1687 or (706) 645-9291, confirmation code
53708100. The webcast and slide presentation will be hosted in the
investor relations section of its corporate Web site at
http://www.valeant.com/. Participants should allow approximately
five to 10 minutes prior to the call's start time to visit the site
and to download any streaming media software needed to listen to
the Internet webcast. An online archive of the webcast will be
available following the end of the live call in the webcast archive
portion of the investor relations section at
http://www.valeant.com/. About Valeant Valeant Pharmaceuticals
International (NYSE:VRX) is a multinational specialty
pharmaceutical company that develops, manufactures and markets a
broad range of pharmaceutical products primarily in the areas of
neurology and dermatology. More information about Valeant can be
found at http://www.valeant.com/. Contact: Laurie W. Little
949-461-6002 (Logo:
http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO
http://photoarchive.ap.org/ DATASOURCE: Valeant Pharmaceuticals
International CONTACT: Laurie W. Little of Valeant Pharmaceuticals
International, +1-949-461-6002, Web Site: http://www.valeant.com/
Copyright